PF 06823859Alternative Names: PF-06823859
Latest Information Update: 11 Aug 2016
At a glance
- Originator Pfizer
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Lupus vulgaris
Most Recent Events
- 16 May 2016 Preclinical trials in Lupus in USA (SC) before May 2016 (NCT02766621)
- 16 May 2016 Preclinical trials in Lupus in USA (IV) before May 2016 (NCT02766621)
- 01 May 2016 Phase-I clinical trials in Lupus (In volunteers) in USA (SC) (NCT02766621)